News | December 19, 2025
Takeda joins BaseLaunch to boost early-stage biotech ventures in Europe
BaseLaunch has supported 27 biotech companies across multiple modalities and indications
BaseLaunch has supported 27 biotech companies across multiple modalities and indications
GS-098, a first-in-class, humanized monoclonal antibody targeting the thyroid-stimulating hormone receptor, is designed to rapidly block the pathogenic activity of thyroid-stimulating autoantibodies
The move strengthens GBL’s clinical-stage presence in the United States
India plays a critical role in Bristol Myers Squibb’s global strategy
Imsidolimab, an IgG4 IL-36 receptor antagonist, works by inhibiting IL-36 receptor signaling, directly addressing the deficiency in the IL-36RA regulator common in GPP patients
Dr Srivastava was selected by an expert jury in recognition of her sustained contributions to renewable chemicals, industrial biotechnology and bioprocess innovation
Ryght AI tackles these hurdles with its AI Site Twin platform
The drug is currently being evaluated in two fully recruited global Phase 3 studies for progressive and tophaceous gout, with results expected in 2026.
The plant can reach an annual capacity of 300 crore tablets and 90 crore capsules
More than five drug candidates from his team progressed to human trials including drugs like Rilematovir (Phase IIb), and Bedaquiline
Subscribe To Our Newsletter & Stay Updated
